UroGen Reports Significant Revenue Growth and Narrowing Losses in Q3 2026
UroGen (URGN) reported strong third-quarter 2026 financial results, characterized by a massive revenue surge to $89 million, up from $27.5 million in the prior year. This growth was primarily driven by the successful commercial scaling of ZUSDURI, which generated $68 million in net product revenue. The company also saw a significant reduction in its net loss, narrowing to just $1.5 million compared to a $33.3 million loss in Q3 2025. Despite the overall growth, JELMYTO revenues declined due to competitive clinical trial enrollment and gross-to-net adjustments. However, management remains optimistic about cash flow, noting that $90.5 million in cash and marketable securities should fund operations through profitability. Looking ahead, the company is focused on the upcoming PDUFA date for UGN-103 in June 2027 and completing Phase 3 enrollment for UGN-104.
Tickers: $URGN
Topics: cash runway commercial scaling net loss reduction revenue growth